Roche breast cancer pill cuts post-surgery recurrence risk by 30% in major trial on December 11, 2025 Adjuvant Therapy ER-positive giredestrant HER2-negative hormone receptor-positive Hormone Therapy Malignant neoplasm of breast oral SERD Recurrence Risk Roche (company) +
FDA Moves to Remove Black Box Warnings from Menopausal Hormone Therapies on November 11, 2025 Black Box Warning estrogens Hormone replacement therapy Hormone Therapy labeling change Menopausal symptom Menopause Progestins United States Food and Drug Administration women 's health +
Roche's Oral SERD Achieves Progression-Free Survival Milestone in Pivotal Breast Cancer Trial on September 23, 2025 advanced breast cancer Clinical Research ER-positive giredestrant Hormone Therapy Malignant neoplasm of breast oral SERD Phase 3 Clinical Trials Progression-Free Survival Roche (company) +